Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iguratimod combined with adalimumab for active rheumatoid arthritis with poor response to csDMARDs
ChiCTR2200055876Phase 4Recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iguratimod and adalimumab in rheumatoid arthritis (RA), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: ACR20 response. Started Dec 2020; status: recruiting.
02
Drugs
iguratimodadalimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2200055876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055876.